Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Retailers seek to shake up clinical trials business
More, but slower, medtech approvals
European regulators probe suicide risk to Ozempic, other Novo drug Saxenda
*please scroll down for all the latest news*
